BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-29@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Novo Nordisk A/S — Insulin icodec [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Research Study to See How a Weekl
 y Insulin\, Insulin Icodec\, Helps in Reducing the Blood Sugar Compared to
  Daily Insulin Glargine\, Both in Combination With Insulin Aspart\, in Adu
 lts With Type 1 Diabetes.\nSource: https://clinicaltrials.gov/study/NCT070
 76199\nhttps://catalystbrief.girapphe.com/e/29?lang=en\nNot investment adv
 ice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/29?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
